Increased Frequency Of Foxp3+ regulatory T cells in mice with hepatocellular carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3815-3819

  Du, Yong ^a   Chen, Xin ^a   Huang, Zhi Ming ^a   Ye, Xiao Hua ^a   Niu, Qing ^b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Foxp3; Granzyme B; Hepatocellular carcinoma; Regulatory T cell

Indexed keywords

EID: 84873644358     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3815     Document Type: Article

References (33)

1. Berbic M, Hey-Cunningham AJ, Ng C, et al (2010). The role of Foxp3+ regulatory T-cells in endometriosis: a potential controlling mechanism for a complex, chronic immunological condition. Hum Reprod, 25, 900-7.
2. Cabrera R, Ararat M, Eksioglu EA, et al (2010). Influence of serum and soluble CD25 (sCD25) on regulatory and effector T cell function in hepatocellular carcinoma. Scand J Immunol, 72, 293-301.
3. Cao X, Cai SF, Fehniger TA, et al (2007). Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity, 27, 635-46.
4. Cederbom L, Hall H, Lvars F (2000). CD4+CD25+ regulatory T cells down-regulate costimulatory molecules on antigen-presenting cells. Eur J Immunol, 30, 1538-43.
5. Gao J, Xie L, Yang WS, et al (2012). Risk factors of hepatocellular carcinoma-current status and perspectives. Asian Pacific J Cancer Prev, 13, 743-52.
6. Ghebeh H, Barhoush E, Tulbah A (2008). Foxp3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer, 8, 50-7.
7. Groux H, O'Garra A, Bigler M, et al (1997). A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature, 389, 737-42.
8. Gupta S, Joshi K, Wig JD, et al (2007). Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol, 46, 792-7.
9. Han Y, Guo Q, Zhang M, et al (2009). CD69+CD4+CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immmunol, 182, 111-20.
10. Herman S, Krenbek D, Klimas M, et al (2012). Regulatory T cells from stable and long-lasting cell cluster with myeloid dendritic cells(DC). Int Immunol, 24, 417-26.
11. Hori S, Nomura T, Sakaguchi S (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science, 299, 1057-61.
12. Huang YH, Zozulya AL, Weidenfeller C, et al (2009). T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible. J Leukoc Biol, 86, 273-81.
13. Junginger J, Schwittlick U, Lemensieck F, et al (2012). Immunohistochemical investigation of Foxp3 expression in the intestine in healthy and diseased dogs. Vet Res, 43, 23.
14. Kalos M (2003). Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine, 21, 781-6.
15. Kiniwa Y, Miyahara Y, Wang HY, et al (2007). CD8+Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res, 13, 6947-58.
16. Kudo M (2010). The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol, 25, 439-52.
17. Liu JY, Zhang XS, Ding Y, et al (2005). The changes of CD4+CD25+/ CD4+ proportion in spleen of tumor-bearing BALB/C mice. J Transl Med, 3, 5.
18. Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90.
19. Luke C, Price T, Roder D (2010). Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population. Asian Pac J Cancer Prev, 11, 1479-85.
20. Miller AM, Lundberg K, Ozenci V, et al (2006). CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol, 177, 7398-40.
21. Mizukami Y, Kono K, Kawaguchi Y, et al (2008). Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer, 98, 148-53.
22. Nummer D, Suri-payer E, Schmitz-Winnenthal H, et al (2007). Role of tumor endothelium in CD4+CD25+regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst, 99, 1188-99.
23. Onizuka S, Tawara I, Shimizu J, et al (1999). Tumor rejection by in vivo administration of anti-CD25(interleukin-2 receptor alpha) monoclonal antibody. Cancer Res, 59, 3128-33.
24. Ormandy LA, Hillemann T, Wedemeyer H, et al (2005). Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 65, 2457-64.
25. Sakaguchi S, Sakaguchi N, Asano M, et al (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune disease. J Immunol, 155, 1151-64.
26. Shimizu J, Yamazaki S, Sakaguchi S (1999). Induction of tumor immunity by removing CD4+CD25+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol, 163, 5211-8.
27. Thakur S, Singla A, Chawla Y, et al (2011). Expansion of peripheral and intratumoral regulatory T cells in hepatocellular carcinoma: a case-control study. Indian J Pathol Microbiol, 54, 448-53.
28. Trapani JA, Smyth MJ (2002). Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol, 2, 735-47.
29. Vignali DA, Collison LW, Workman CJ (2008). How regulatory T cells work. Nat Rev Immunol, 8, 523-32.
30. Weiner HL (2001). Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev, 182, 207-14.
31. Workman CJ, Szymczak-workman AL, Collison LW, et al (2009). The development and function of regulatory T cells. Cell Mol Life Sci, 66, 2603-22.
32. Zheng SG (2008). The critical role of TGF-β1 in the development of induced Foxp3+ regulatory T cells. Int J Clin Exp Med, 1, 192-202.
33. Zhou J, Ding T, Pan W, et al (2009). Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer, 125, 1640-8.